Merger Announcement between INVO Bioscience and NAYA Biosciences
SARASOTA, Fla. and MIAMI - INVO Bioscience announced a significant milestone in the biopharmaceutical sector today, marking the successful closure of its merger with NAYA Biosciences. This strategic alliance aims to enhance patient access to pioneering treatments in oncology and autoimmune diseases.
New Company Name and Operations
Post-merger, INVO Bioscience will adopt the name NAYA Biosciences and trade under the ticker "NAYA" on NASDAQ. The new entity plans to leverage its existing revenue-generating fertility division while broadening its efforts toward developing innovative, first-in-class clinical stage assets targeting serious health conditions.
Leadership Team Shaping the Future
Steve Shum, the CEO of INVO, will continue to lead as the CEO of the merged company. Andrea Goren will serve as the Chief Financial Officer alongside a robust leadership team that includes Dr. Daniel Teper as President. Dr. Teper, with over three decades of strategic leadership within biotech, will also head NAYA Therapeutics.
Insights from Top Executives
According to CEO Steve Shum, the merger will create substantial value through an integrated portfolio, combining the stability of their fertility business with the growth potential from cutting-edge therapeutics. This will optimize risk-return ratios for investors, driving value in both legacy and new shareholders.
Clinical Trials and Innovative Therapies
The combined resources will also enhance the development of new treatments. Dr. Teper expressed enthusiasm about their lead GPC3-targeting FLEX-NK™ bispecific antibody, set for Phase I/II clinical trials, which aims to meet critical needs in treating hepatocellular carcinoma. Additionally, their CD38-targeting FLEX-NK™ antibody shows promise in the competitive multiple myeloma market and unmet autoimmune disease needs.
Details of the Merger Agreement
The merger was executed through a reverse triangular agreement, where INVO gained complete ownership of NAYA. As part of this agreement, INVO distributed a combination of common and preferred stocks to with NAYA's security holders. The inclusion of beneficial ownership limitations highlights strategic operational planning. Stakeholders will benefit as the stock converts into common shares, allowing for operational robustness and strategic growth.
Looking Ahead: The Strategic Vision
Both companies are optimistic about their growth trajectory as a unified organization. The merger grants increased capital access and shared resources to fast-track product development within their pipelines. This symbiotic relationship is expected to foster innovation and efficiency.
Importance of Board Composition
Under the newly unified board, two members from NAYA, Dr. Teper and Ms. Lyn Falconio, will collaborate with existing INVO board members. This diverse leadership will ensure that the goals and strategies reflect a comprehensive market understanding for sustained growth.
Stakeholder Interests
With the merger not requiring the approval of INVO shareholders, the closing solidifies a mutual agreement aimed at enhancing stockholder value. This fortified structure is indicative of a forward-thinking approach to its business model, reinforcing their commitment to innovative healthcare solutions.
Frequently Asked Questions
What is the outcome of the INVO and NAYA merger?
The merger results in the formation of NAYA Biosciences, which will focus on oncology and autoimmune disease treatments while maintaining its existing fertility business.
Who leads the new NAYA Biosciences company?
The leadership will be headed by INVO's CEO Steve Shum and Dr. Daniel Teper, founder of NAYA, who will also assume the role of President.
What are the potential benefits of this merger?
This merger is expected to enhance access to capital, promote shared resources for accelerated development, and create significant value for shareholders.
What innovative treatments are being developed post-merger?
The company aims to advance clinical trials for its GPC3-targeting FLEX-NK™ bispecific antibody as well as other promising therapeutic candidates.
How will shareholder equity be affected?
Stakeholders prior to the acquisition are expected to hold a substantial 17.75% of the combined entity's equity, reflecting a solid return on their investment.
